In addition, Catholic Healthcare West (CHW) has received Institutional Review Board approval for the clinical trial, which is expected to begin soon. Advanced Cell Technology’s (ACT) myoblast program is an autologous adult stem cell therapy for the treatment of heart disease that has successfully completed four Phase I clinical trials and received clearance from the FDA to begin Phase II trials.
William Caldwell, IV, chairman and CEO of ACT, said: “The agreement with CHW signifies our readiness to begin the Phase II clinical trial. We are excited to begin the trial, which has the potential to be a major advance for the field of regenerative medicine and, more importantly, to patients in need of care.”